Baxter International (BAX) investor relations material

Leadership reflections and strategic direction

• CEO emphasized a renewed focus on execution, leveraging Baxter's strong brand and customer trust.

• Introduced a three-point plan: stabilize the business, de-lever the balance sheet, and drive continuous improvement.

• Launched Baxter GPS (Growth and Performance System) and shifted to a decentralized model with eight key value creators.

• Prioritized capital allocation and removed the dividend to focus on reducing leverage below 3x by year-end.

• Leadership is driving a culture of high engagement, continuous improvement, and accountability at all levels.

Business performance and operational updates

• Current year is focused on stabilization, with flat or low single-digit growth expected; return to market growth anticipated next year.

• IV utilization and hospital behavior have reached a new normal, with business right-sized and stabilization expected by year-end.

• Pharma and injectables businesses were combined for synergy; operational improvements are underway at challenged sites.

• Compounding business is outpacing market growth, driven by execution and customer value, with a focus on improving margins.

• HST segment is rationalizing SKUs, investing in high-growth areas like Bardy, and launching new products such as a stretcher platform.

Financial outlook and capital allocation

• Gross margin headwinds from divestitures, tariffs, and higher manufacturing costs are expected to ease in the second half.

• Operating margin is projected to expand by over 500 basis points in the back half of the year, driven by volume and cost actions.

• Normalized P&L is expected in the second half, providing a clearer view of earnings power for 2026 and beyond.

• Capital allocation priorities include internal investment, debt repayment, dividends, share buybacks, and M&A, with flexibility increasing as leverage falls below 3x.

• Future capital deployment will balance internal growth, M&A, and buybacks, aiming for long-term shareholder value.